Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VK sold cybersports club Virtus.pro for ₽174 million

3/17/23 VKCO

Sovcomflot reported for 2022 according to RAS

3/17/23 FLOT

Nokian Tyres received payment from Tatneft for tire business in Russia

3/17/23 TATN

FedEx reported for 9 months of fiscal year 2023

3/17/23 FDX

Aerojet shareholders agreed to sell L3Harris

3/17/23 AJRD

Aerojet shareholders agreed to sell L3Harris

3/17/23 LHX

Novatek's 2022 RAS profit doubled

3/16/23 NVTK

Fesco may buy a container terminal in St. Petersburg

3/16/23 FESH

Rostelecom will reach its strategy goals sooner than planned

3/16/23 RTKM

The Hello Group (Momo) announced a quarterly dividend

3/16/23 MOMO